Results 111 to 120 of about 106,290 (280)

Participation of pro-inflammatory cytokines in neuropathic pain evoked by chemotherapeutic oxaliplatin via central GABAergic pathway

open access: yesMolecular Pain, 2018
Background Neuropathic pain is observed in patients as chemotherapeutic oxaliplatin is used to treat metastatic digestive tumors; however, the mechanisms responsible for hyperalgesia are not well understood.
Dongsheng Xu   +5 more
doaj   +1 more source

Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells

open access: yesChemistry – A European Journal, EarlyView.
ABSTRACT Fluorouracil‐platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs PtIVP‐5FUMeOBut and PtIV56‐5FUMeOBut were actualized by derivatising the clinical drug 5‐fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of ...
Maria George Elias   +9 more
wiley   +1 more source

Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study

open access: yesHead &Neck, EarlyView.
ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange   +16 more
wiley   +1 more source

Oxaliplatin versus irinotecan as first-line therapy in metastatic colorectal cancer with prior adjuvant treatment: a retrospective study on efficacy, sequential therapy, and the impact of thrombocytopenia

open access: yesFrontiers in Oncology
BackgroundThe comparative efficacy of oxaliplatin versus irinotecan as first-line therapy in mCRC patients with prior adjuvant treatment remains unclear.ObjectivesTo compare the efficacy of first-line oxaliplatin-based versus irinotecan-based ...
Han Shan   +8 more
doaj   +1 more source

Adapting tumor interstitial fluid pressure for intraperitoneal chemotherapy [PDF]

open access: yes, 2014
C
Ceelen, Wim   +5 more
core   +1 more source

Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis

open access: yesMolecular Medicine
Background Chemotherapy resistance is a major challenge in the treatment of intermediate and advanced gastric cancer (GC). This study aimed to recognize oxaliplatin resistance-related genes (OXARGs) in GC and to explore their role and mechanism in ...
Yan Zhang   +6 more
doaj   +1 more source

Identification of a signature gene set for oxaliplatin sensitivity prediction in colorectal cancer

open access: yesFrontiers in Oncology
BackgroundColorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Oxaliplatin-based chemotherapy is a cornerstone of treatment for many CRC patients; however, the development of chemoresistance severely limits its therapeutic ...
Xiaopeng Zhan   +9 more
doaj   +1 more source

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

open access: yesInternational Journal of Cancer, EarlyView.
What's New? This study introduces a novel approach for detecting locally advanced esophageal carcinoma using cell‐free DNA (cfDNA) analysis through a highly sensitive fragmentome assay. Unlike traditional sequencing‐based methods that are limited by the absence of specific mutations in esophageal tumors, our method offers an alternative by quantifying ...
Anouchka Modesto   +21 more
wiley   +1 more source

Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer

open access: yesJournal of Translational Medicine
Background Oxaliplatin resistance usually leads to therapeutic failure and poor prognosis in colorectal cancer (CRC), while the underlying mechanisms are not yet fully understood.
Yuting Huang   +11 more
doaj   +1 more source

Globo‐H diagnostic stratification and identification of DUSP14 as a candidate target in colorectal cancer

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Colorectal cancer (CRC) is increasingly complicated by drug‐resistant tumors that limit the effectiveness of anticancer therapies. Because resistance mechanisms vary among patients and can evolve over time, personalized treatment strategies are needed.
Keren Zohar   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy